Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Shiren S. Lee Ph.D. | Chairman, Manager & President | -- | -- | 1961 |
| Yu Jun Zhang | Commissioner of Finance Department | -- | -- | -- |
| Jinghua Zeng | Accounting Supervisor | -- | -- | -- |
| Yi Xuan Zhang | Commissioner of Marketing Business Department | -- | -- | -- |
| Qiu Yue Li | MD & Director | -- | -- | -- |
| Jiang Ming-Wei | MD & Director | -- | -- | -- |
TAHO Pharma
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 14
Description
Taho Pharmaceuticals Ltd., a pharmaceutical company, develops products using transdermal and transmucosal systems in Taiwan. The company's portfolio includes TAH4411 Ondansetron ODF for the treatment of chemotherapy-induced nausea and vomiting; TAH3311 apixaban oral film, which is in phase 3 clinical trial for patients with Dysphagia; TAH3341 apixaban oral extend release film for patients with Dysphagia; TAH2211 Buprenorphine/Naloxone sublingual film, which is in phase 1 clinical trial for opioid addiction; TAH2231 Naloxone Buccal film , which is in phase 1 clinical trial for opioid overdose; TAH9922 atomoxetine oral liquid, which is in phase 1 clinical trial; and TAH9901 methylphenidate patch, which is in phase 1 clinical trial for the treatment of deficit and hyperactivity disorder. The company was founded in 2010 and is based in Taipei, Taiwan.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available